These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2091 related articles for article (PubMed ID: 32394467)
21. Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review. Giovane RA; Rezai S; Cleland E; Henderson CE Rev Med Virol; 2020 Sep; 30(5):e2136. PubMed ID: 32644275 [TBL] [Abstract][Full Text] [Related]
22. Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production. Fintelman-Rodrigues N; Sacramento CQ; Ribeiro Lima C; Souza da Silva F; Ferreira AC; Mattos M; de Freitas CS; Cardoso Soares V; da Silva Gomes Dias S; Temerozo JR; Miranda MD; Matos AR; Bozza FA; Carels N; Alves CR; Siqueira MM; Bozza PT; Souza TML Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32759267 [TBL] [Abstract][Full Text] [Related]
23. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents. Khadke S; Ahmed N; Ahmed N; Ratts R; Raju S; Gallogly M; de Lima M; Sohail MR Virol J; 2020 Oct; 17(1):154. PubMed ID: 33059711 [TBL] [Abstract][Full Text] [Related]
24. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus. Costanzo M; De Giglio MAR; Roviello GN Curr Med Chem; 2020; 27(27):4536-4541. PubMed ID: 32297571 [TBL] [Abstract][Full Text] [Related]
26. Current pharmacological treatments for SARS-COV-2: A narrative review. Nittari G; Pallotta G; Amenta F; Tayebati SK Eur J Pharmacol; 2020 Sep; 882():173328. PubMed ID: 32603692 [TBL] [Abstract][Full Text] [Related]
27. Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review. Vargas M; Servillo G; Einav S Eur Rev Med Pharmacol Sci; 2020 Aug; 24(16):8592-8605. PubMed ID: 32894567 [TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis. Liu W; Zhou P; Chen K; Ye Z; Liu F; Li X; He N; Wu Z; Zhang Q; Gong X; Tang Q; Du X; Ying Y; Xu X; Zhang Y; Liu J; Li Y; Shen N; Couban RJ; Ibrahim QI; Guyatt G; Zhai S CMAJ; 2020 Jul; 192(27):E734-E744. PubMed ID: 32493740 [TBL] [Abstract][Full Text] [Related]
29. H Yang G Am J Physiol Cell Physiol; 2020 Aug; 319(2):C244-C249. PubMed ID: 32515982 [TBL] [Abstract][Full Text] [Related]
30. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Guo YR; Cao QD; Hong ZS; Tan YY; Chen SD; Jin HJ; Tan KS; Wang DY; Yan Y Mil Med Res; 2020 Mar; 7(1):11. PubMed ID: 32169119 [TBL] [Abstract][Full Text] [Related]
31. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Choy KT; Wong AY; Kaewpreedee P; Sia SF; Chen D; Hui KPY; Chu DKW; Chan MCW; Cheung PP; Huang X; Peiris M; Yen HL Antiviral Res; 2020 Jun; 178():104786. PubMed ID: 32251767 [TBL] [Abstract][Full Text] [Related]
32. Teicoplanin: an alternative drug for the treatment of COVID-19? Baron SA; Devaux C; Colson P; Raoult D; Rolain JM Int J Antimicrob Agents; 2020 Apr; 55(4):105944. PubMed ID: 32179150 [TBL] [Abstract][Full Text] [Related]
33. Antiviral therapy for coronavirus disease 2019. Gong S; Su J; Yan X; Li F; Hu L; Liu S Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2020 May; 45(5):598-602. PubMed ID: 32879113 [TBL] [Abstract][Full Text] [Related]
34. Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery. Sternberg A; McKee DL; Naujokat C Curr Top Med Chem; 2020; 20(16):1423-1433. PubMed ID: 32416679 [TBL] [Abstract][Full Text] [Related]
35. Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19. Sun J; Chen Y; Fan X; Wang X; Han Q; Liu Z Postgrad Med; 2020 Sep; 132(7):604-613. PubMed ID: 32496926 [TBL] [Abstract][Full Text] [Related]
36. Cholesterol 25-Hydroxylase inhibits SARS-CoV-2 and other coronaviruses by depleting membrane cholesterol. Wang S; Li W; Hui H; Tiwari SK; Zhang Q; Croker BA; Rawlings S; Smith D; Carlin AF; Rana TM EMBO J; 2020 Nov; 39(21):e106057. PubMed ID: 32944968 [TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis. Zhong H; Wang Y; Zhang ZL; Liu YX; Le KJ; Cui M; Yu YT; Gu ZC; Gao Y; Lin HW Pharmacol Res; 2020 Jul; 157():104872. PubMed ID: 32360583 [TBL] [Abstract][Full Text] [Related]
38. Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past. Shah VK; Firmal P; Alam A; Ganguly D; Chattopadhyay S Front Immunol; 2020; 11():1949. PubMed ID: 32849654 [TBL] [Abstract][Full Text] [Related]
39. Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses. Theerawatanasirikul S; Kuo CJ; Phecharat N; Chootip J; Lekcharoensuk C; Lekcharoensuk P Antiviral Res; 2020 Oct; 182():104927. PubMed ID: 32910955 [TBL] [Abstract][Full Text] [Related]
40. Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets. Park SJ; Yu KM; Kim YI; Kim SM; Kim EH; Kim SG; Kim EJ; Casel MAB; Rollon R; Jang SG; Lee MH; Chang JH; Song MS; Jeong HW; Choi Y; Chen W; Shin WJ; Jung JU; Choi YK mBio; 2020 May; 11(3):. PubMed ID: 32444382 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]